Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Pure Bioscience, Inc. (PURE) Gets Good News on SDC

PURE Bioscience, developers of bioscience products for combating stubborn bacteria such as Staph (MRSA), announced today that its patented antimicrobial product SDC (silver dihydrogen citrate) has been shown to be effective based upon tests conducted by the University of Medicine & Dentistry of New Jersey. The tests demonstrated SDC’s effectiveness against bacterial films, common in any nutrient-sufficient ecosystems, such as oral cavities.

Dr. Narayanan Ramasubbu, Associate Professor with the Department of Oral Biology at the university, described the study and its results. “We have used SDC against single species biofilms of Aggregatibacter actinomycetemcomitans, a causative agent in localized aggressive periodontitis, and S. epidermidis, a pathogen associated with hospital settings. Our results show that these bacteria in the biofilm state are killed within minutes at 30 ppm of SDC. Not only did SDC kill biofilm bacteria but also it inhibited the biofilm formation at levels as low as 1.5 ppm in a citrate-containing medium.”

According to Dr. Ramasubbu, biofilms play a role in the pathogenesis of dental caries, periodontitis, infective endocarditis, cystic fibrosis, pneumonia, prostatitis, osteomyelitis, otitis media, infectious kidney stones, and other chronic infections, and that they can be comprised of a single microbial species or multiple microbial species, requiring very specific, highly effective, and environmentally safe agents that can adapt to resistance.

PURE’s President and CEO, Michael Krall, commented on the development. “SDC’s ability to eliminate and even prevent biofilm presents a phenomenal market opportunity for PURE. We’re directing ongoing research projects on biofilm not only in public health, but also in industrial environments, including food processing, and oil and gas, as we begin to present SDC as a viable solution to this costly and dangerous problem.”

SDC is an electrolytically generated source of stabilized ionic silver, which can be joined with other compounds to provide superior antimicrobial efficacy with residual protection while mitigating bacterial resistance.

For additional information, visit the company’s website at

Let us hear your thoughts below:

This entry was posted in Small Cap News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *